Spark Biopharma logo — Harnessing image-based screening and target protein identifi...

Spark Biopharma

Harnessing image-based screening and target protein identification to accelerate innovative drug development.

Founded 2016 Series C Total: $28.00B Biotechnology, Health Care

General Information

Company Name Spark Biopharma
Founded Year 2016
Founders / Decision Makers
Team member
Industries Biotechnology, Health Care
Funding Stage Series C
Social

Get notified when Spark Biopharma moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Spark Biopharma

Spark Biopharma is a biotechnology startup founded in 2016 at Seoul National University. The company specializes in harnessing image-based screening and target protein identification to expedite the development of innovative drugs. Leveraging proprietary drug molecule diversity technology and a unique fluorescent skeleton probe, Spark Biopharma is dedicated to identifying and developing novel drug candidates. The company recently received a KRW25.00B Series C investment on April 4, 2022, with notable investors including Company K Partners, KB Investments, IMM Investment, Timefolio Asset Management, WE Ventures, Medytox Venture Investment, Shinhan Venture Investment, Kiwoom Investment, DAOL Investment & Securities, and Dt& Investment. With a focus on strategic collaborations with both domestic and international research institutes and pharmaceutical organizations, Spark Biopharma aims to accelerate drug development speed and success rates in the biotechnology and healthcare industries.

Taxonomy: drug development, pharmaceutical research, technology, image-based screening, target protein identification, drug candidates, innovation, fluorescent skeleton probe, research institutes, pharmaceutical organizations, Seoul National University, drug molecule diversity, success rate, strategic cooperation

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series C •••••• 10
Investor Investor Investor Investor Investor Investor Investor Investor Investor
•••• ••••
04 Apr 2022
Series B •••••• - 25 Nov 2021
Venture Round •••••• - 01 Jan 2018

Spark Biopharma Alternatives & Competitors

Spark Biopharma vs

Utilizing advanced AI to discover new drug candidates by scanning extensive libraries of chemical co...

Series A
2-10 employees
AI, Health Care
Spark Biopharma vs

Innovative drug delivery solutions enhancing the development and improvement of pharmaceuticals sinc...

Series B
Biotechnology, Health Care
Spark Biopharma vs

Delivering Excellence in Drug Research and Development with Industry-Leading Expertise

Series B
Biotechnology, Health Care

FAQ About Spark Biopharma

Harnessing image-based screening and target protein identification to accelerate innovative drug development.
Spark Biopharma was founded in 2016.
Spark Biopharma operates in the following industries: Biotechnology, Health Care.
Spark Biopharma has completed 3 funding rounds, raising a total of $28.00B. The latest funding stage is Series C.
Top alternatives and competitors to Spark Biopharma include X-37, Bostal Drug Delivery, BociMed, UPPTHERA, Inc., Suven Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Spark Biopharma and X-37 are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Spark Biopharma and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

One analytics cookie (Google Analytics). Cookie Policy